Research Output Journal of Biological and Applied Science 5(3):140-147, 2025

ROJBAS Publications ONLINE ISSN: 1115-9200

https://rojournals.org/roj-biological-and-applied-science/ PRINT ISSN: 1115-6120

https://doi.org/10.59298/ROJBAS/2025/53140147

Understanding the Human Microbiome: Implications for Health

Nassimbwa Kabanda D.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

The human microbiome, a complex ecosystem of bacteria, viruses, fungi, and other microorganisms residing in and on the human body, plays a critical role in maintaining health and mediating disease. This chapter explores the intricate dynamics of the microbiome, its development across the lifespan, and its bidirectional interactions with diet, immune function, metabolism, mental health, and chronic disease progression. Advances in DNA sequencing technologies and metagenomics have uncovered profound individual variability and previously unrecognized microbial taxa, deepening our understanding of how the microbiome supports immunity, nutrient absorption, and psychological resilience. The review underscores how perturbations such as antibiotic use, dietary shifts, and environmental exposures may disrupt microbial homeostasis, leading to dysbiosis and contributing to conditions like obesity, inflammatory bowel disease, depression, and cardiovascular disorders. By analyzing microbial compositions and their metabolites, researchers are beginning to develop targeted therapeutic strategies, including prebiotics, probiotics, and microbiota-directed interventions. Despite ongoing challenges in mechanistic understanding and clinical translation, the microbiome represents a promising target for precision medicine and public health interventions.

Keywords: Human Microbiome, Gut Microbiota, Dysbiosis, Immune System, Mental Health, Chronic Diseases, Microbial Metabolites.

INTRODUCTION

The human microbiome consists of all microbes associated with the body, distinguished from environmental microbiomes found in fixed locales. This chapter focuses solely on the human microbiome, revealing that the number of microbial cells is comparable to somatic cells, with microbial genes vastly outnumbering those in the human genome. However, considerable variation exists among individuals in their microbial compositions, and the reasons behind this variability remain largely unexplained. Significant advances have been made in analyzing large genomic data from complex microbial communities. Enhanced DNA sequencing accuracy has deepened our understanding of microbiome structure and function in both health and disease. The chapter discusses the benefits of using 16S rRNA gene sequences for analyzing microbial communities and their interactions with human biology. A healthy microbiome is crucial for well-being, providing nutrients, protecting against pathogens, and aiding immune development. Disruptions in microbiome diversity often occur due to factors like starvation, illness, and antibiotics. Such perturbations are associated with conditions like obesity, inflammatory bowel disease, and autism. Research indicates that the impact of perinatal antibiotics and a lack of diverse gut microbes may predispose children to obesity, emphasizing the importance of a balanced early microbiome for metabolic health [1, 2].

Historical Perspectives

The human microbiome has been a long-standing area of research that has gained renewed attention with the advent of new sequencing technologies. Human-associated microbes can be viewed as a secondary genome that has co-evolved with their hosts, profoundly influencing host development, immunity, and metabolism. Together with their metabolites, these microbes modulate a host's susceptibility to a range of

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

diseases. However, the number and types of microorganisms inhabiting a body and their links to health and disease are poorly understood. Recent advances in DNA sequencing and bioinformatics have made it possible for researchers to catalogue the diversity of microbial species in human samples. These studies have developed an unprecedented picture of microbial diversity that has sparked an avalanche of follow-up research into the human microbiome's links to metabolic and immune diseases, cancers, and mental disorders. These studies are also defining the reference microbiome of different habitats. Questions can now be asked regarding the differences and evolutions in the human microbiome and those of our ancestors, and how the microbiome has changed in response to changes in diets and cultures over a much longer timeframe. These studies have only begun to scratch the surface of understanding the roles played by microbes in human health and disease. Although advances in sequencing technologies and bioinformatics have enabled researchers to identify and catalogue a diverse set of microbial species, how these microorganisms interact with each other, with their hosts, and the environment, and how these interactions change over time are still poorly understood. These interactions challenge the current approaches and traditional one-by-one mechanistic studies of microbes that have dominated our understanding of host-microbe interactions [3, 4].

Composition of the Microbiome

Multiple overlapping factors shape microbiome composition, but most studies focus on diet. The authors explore the implications of other factors and their mechanisms in shaping the microbiome. While the diet's impact on health is established, the link between diet, microbiome, and health is complex. Dietary changes alter microbiome composition, creating a bidirectional interaction that complicates our understanding of microbiome structure and environmental factors. Research on childhood microbiome shifts indicates that several factors, including diet, affect microbiome diversity, influencing immune function and metabolic reactions. Recent interventions highlight the benefits of fermented foods on gut microbiome composition and systemic inflammation in healthy older adults. Enhanced microbiome diversity correlates with decreased serum inflammatory biomarkers like TNF-alpha and IL. Microbiome analysis reveals that immune modulation relates to increased diversity and unexplored taxa such as Alistipes and Faecalibacterium. 16S WGS sequencing shows a significant but temporary change in microbiome composition post-diet intervention, suggesting a complex interaction that needs further study. One key question is understanding the different responses to various foods, possibly linked to a lack of fiber-degrading microbes. The gut microbiota's role in fermenting dietary fibers to produce SCFAs is crucial. Responder microbiomes were enriched in Prevotella copri with reduced Bacteroides. Notably, gut microbiota responses evolved during the intervention, showing a common reduction in Desulfovibrio. Additionally, gut microbial taxa may be involved in immune-modulating SCFA production, correlating with inflammation reduction in those on a standard diet [5, 6].

Microbiome Development across the Lifespan

The human microbiome is a focus of microbiome studies, propelled by advancements in sequence-based microbial profiling, yet it remains among the least understood areas of human system biology. The birthing process significantly influences microbial encounters, though microbial colonization likely begins with the mother even before birth. Initial microbial exposure for humans occurs at membrane rupture, allowing waterborne microorganism's access to the womb's sterile environment. This exposure likely stimulates the developing immune system, triggering the formation of the first phagocytic immune cells. The impact of maternal microbial exposures on the fetal microbiome and the development of both innate and adaptive immunity establishes the foundation for a lifelong, health-protecting host-microbiome symbiosis. Understanding how a healthy infant gut microbiome is established is crucial for creating health-promoting products and interventions. Recent developments enable high-throughput microbial composition and metagenomics profiling, offering a formalized approach to research. The current interest in infant gut microbiome establishment is reflected in pilot cohort studies that illuminate this complex developmental process. However, challenges remain, including the need for systems biology approaches and interdisciplinary integration. Despite these hurdles, there is optimism that the creation of targeted pre- and probiotics aimed at nurturing infant gut microbiome development is on the horizon [7, 8].

Microbiome and Immune Function

The human microbiome is a consortium of billions of microbial organisms that exists in and on the human body. It includes bacteria as well as fungi, archaea, viruses, and protozoa. There are at least 1 trillion microbes on and in the average person, composed of 500 to 1,000 orthologous bacterial species. Each of these bacteria lives as part of a social community called a biofilm, which may consist of up to a million

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

cells per individual biofilm. Not only are microbes ubiquitous, but they often outnumber cells of the host itself many times over. While some bodily areas are considered "sterile" (e.g., the cervix, uterus, kidneys, and blood), most body sites are colonized by microbes very early on in life. The understanding of how microbes colonize human tissues is increasingly understood. The physiology of these organisms and their host populations living together in some form of homeostasis is a vast subject that is outside the scope of this article. Nevertheless, the microbial population in the human body is in a constant state of flux. The normal, steady-state ensemble of microbes is referred to as the "microbiota." A composition that is relatively stable over time is referred to as a "microbiome." Changes in microbial composition are referred to as "dysbioses." Identifying how dysbioses develop over time, what triggers them, and how they relate to the onset of disease is a primary goal of the field. It is also known that the microbiome strongly influences the immune system. This influence consists of: (1) preventive effects, for instance, the prevention of colonization by infectious organisms; and (2) immunological effects, in which the immune system is directed in such a way that a normal homeostatic reliance on the digestion of food is maintained. It is also increasingly clear that wildlife and livestock produce specific chemical signals, microbiota, and hormones that induce systemic pro- or anti-inflammatory responses in land-based mammals, including humans [9, 10].

Micro-biome and Metabolism

The human microbiome comprises bacteria, viruses, fungi, bacteriophages, and other organisms that interact with each other and their host. The microbiome composition is unique to each individual, established shortly after birth, and maintained throughout life. It is believed that the microbiome composition is crucial for lifelong health; recent discoveries implicating the microbiome in diseases ranging from inflammatory bowel disease to schizophrenia have been paradigm-shifting for many disciplines. These findings raise critical questions about how the microbiota influences health status. Insight into the molecular mechanisms linking microbiota to health status may assist in identifying high-risk individuals and intervention opportunities. The gut microbiome, located at the crucial interface between exogenous dietary intake and internal nutrient metabolism, is of particular interest for investigating the relationship between the microbiome and health. Microbes and microbial metabolites can translocate from the intestine into the bloodstream in the absence of intestinal diseases. The gut microbiome is likely to play a major role with habitual diet in determining gut mucosal membrane permeability and influencing systemic inflammation. Factors determining the specific population of microbiota in humans remain concerted, but diet is key. Microbial metabolism catalyzes the degradation of otherwise indigestible dietary components. Specific dietary components act as substrates for microbial metabolism and may serve to shape microbiome composition/function. The gut microbial metabolism of an animal product-derived carnitine to the pro-atherogenic metabolite trimethylamine N-Oxide (TMAO) has been shown to associate with increased risk of atherosclerosis. Therefore, diet is hypothesized to be associated with the composition of the microbiome in healthy humans, and microbiome composition is hypothesized to be associated with gut and plasma metabolite compositional differences. Dietary intake data and biological samples obtained from participants are quantitatively analyzed using untargeted big data sequencing platforms and bioinformatics pipelines. Each metabolomic platform's performance is evaluated by determining its reproducibility, sensitivity, and sample [11, 12].

Microbiome and Mental Health

Mental health is described as the ability of an individual to reach their potential, cope with normal stressors, work productively, and contribute to the community (i.e., good sentiment and cognition). This is inextricable from physical health, as without mental health, there can be no true physical health (i.e., comprehensible bodily homeostasis). However, recent data suggest that recent cohorts in Westernized nations do not appear to be better off psychologically. Depression is associated with elevations in C-reactive protein (CRP), inflammatory cytokines (including IL-6, IL-1, TNFα, NFκB), oxidative stress (lipid peroxidation), and pro-inflammatory transcription factors (NFκB), biomarkers of low-grade inflammation. Low-grade inflammation and associated biological dysregulations are at the center of a complex cascade resulting from the interplay of dietary patterns, psychological stress, environmental exposures, and lifestyle variables relevant to most non-communicable diseases (NCDs), including depression. The gut microbiome may strongly influence human health in ways that include and extend beyond immune mechanisms. Human intestinal microbes are exposed to the diet in the gut, which is also the location of fermentation and absorption of many dietary components. The majority of the metabolic breakdown products in peripheral tissues originate from this bio flora-generated fermentation of dietary

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

material, particularly fiber. The gut microbiome is now understood to influence the activity and expression of more than 600 human host genes and genes encoding for neurotransmitters, both in the gut and in the brain. Associations between anxiety and/or depressive symptoms and Mediterranean, traditional Japanese, "Western," and various high-fibre dietary patterns have been identified across diverse populations. These could be partly explained by microbiome-mediated alterations to host metabolism, inflammatory responses, and neurobiology. Many lifestyle-based interventions that improve mental health may also reshape the gut microbiome. This evidence-based approach offers potential models to identify processes and etiological mechanisms by which diet and gut microbiota might influence mental health. Additionally, the microbiome does complicate the interpretation of concepts of "healthier" diets, as differences among populations and ethnicities regarding optimal diets may coexist [13, 14].

Microbiome and Gastrointestinal Health

The human gastrointestinal microbiota is an incredibly diverse collection of trillions of microorganisms, with a primary composition of bacteria that boasts a gene count that remarkably surpasses that of all human genes combined. This intricate microbiota plays a vital role in maintaining overall health, significantly influencing critical processes such as nutrient absorption, metabolism, and the functional aspects of immunity. A state known as dysbiosis, which refers to a disruption in the balance of this microbiota, is increasingly being linked to a wide array of gastrointestinal disorders as well as systemic diseases that affect various parts of the body. The complex architecture of the human gastrointestinal tract provides an optimal environment that supports a rich diversity of microbial life, thanks to its abundant resources and variabilities in conditions throughout the tract. Many different factors, including individual genetics, advancing age, dietary habits, and overall lifestyle choices, all converge to impact the composition of the microbiota. This composition is now acknowledged as a dynamic and constantly changing ecosystem comprising bacteria, archaea, viruses, and eukarya. Recent technological advances in massively parallel pyrosequencing have unfolded this complexity, thereby prompting a wealth of new research into the intricate structural and functional aspects of the microbiota, as well as its various health implications. Contemporary studies are increasingly focused on exploring gut microbial interactions, understanding the influences of diet, and delving into the realm of precision nutrition, employing cutting-edge high-throughput sequencing techniques and advanced bioinformatics. This burgeoning field is emerging as a particularly promising area of biomedical research, holding significant potential for future health interventions and therapeutic innovations [15, 16].

Microbiome and Chronic Diseases

Evidence from molecular, preclinical, population-based, and clinical studies supports the role of the human microbiome (HMB) in the development or protection from many chronic diseases, including various types of cancer, allergies, diabetes mellitus, obesity, celiac disease, inflammatory bowel disease (IBD), cardiovascular disease, psychological disorders, neurodegeneration or dementia. The influence of the HMB on top-tier conditions, including type 1 diabetes, chronic obstructive pulmonary disease/lung disease, hypertension, asthma, metabolic syndrome, hyperlipidemia, rheumatoid arthritis, multiple sclerosis, multiple chronic conditions, has also begun to be elucidated, and microbiome-targeted interventions or prebiotics/probiotics hold potential for clinical application. The expected clinical applications of the human microbiome in the prevention or protection from 22 public health risk factors and top-tier chronic diseases, and risk factors were summarized based on the first available evidence, with a special focus on IBD, colorectal cancer, and fatness, which are conditions with already available knowledge ready for further clinical studies and applications. The dietary influence of gut microbiota microbes on macronutrient metabolism due to the production of SCFAs and various other metabolites is reviewed in the context of the association of obesity, insulin resistance, type 2 diabetes mellitus, dyslipidemia, and fatty liver disease in the pathogenesis of MS. The potential roles and mechanisms of gut microbiota composition and activity are explored for infection-associated chronic disease, asthma, obesity, metabolic syndrome, IBD, cardiovascular disease, and chronic liver disease (CLD), with a specific focus on NAFLD, nonalcoholic fatty liver disease, and chronic hepatitis B virus infection. The challenges posed by the use of oral antibiotics and pre- and probiotics on the composition and the increased pathogenicity of gut microbiota bacteria are also addressed. In a discussion for future directions, it is emphasized that caution must be exercised regarding the late-breaking and premature association of microbiota with chronic diseases, while current applications are reviewed or listed to prevent discrediting the importance of microbiota knowledge that has already been obtained [17, 18].

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Factors Influencing the Microbiome

The microbes inhabiting humans and other organisms significantly affect host development, resilience, and function. Each microscale habitat encourages interactions among microbial communities and hosts, enhancing health. The interplay at the microbial-organism interface guides microbiota development, influencing homeostatic responses of both microbes and hosts. These interdependencies occur through immune maturation, microbial metabolite interactions, epigenetic gene regulation, and changes in host metabolism. Disruptions in microbiome-related chemical exchanges can lead to dysfunction and disease. Humans and many animals possess stable microbiota that supports health, yet its maturation can be disrupted by various events, potentially causing health issues. Understanding the systems maintaining microbiome health is crucial for microbiome research and medicine. Over the past decade, efforts have focused on the impact of spatial ecology and population dynamics in shaping microbial interactions and microbiome function. However, modeling these factors at a systems level poses challenges; experimental systems must accommodate long spatial and evolutionary timescales, alongside the development of computational techniques for large-state-space modeling of biophysical networks. These approaches may also aid in analyzing community behavior in colonization or microbial ecology studies. Progress in these areas will enhance comprehension of interspecies communication dynamics and the behavior of complex multicellular organism consortia, potentially leading to the design of artificial microbiomes [19, 20].

Therapeutic Applications of Microbiome Research

Microbiome-based therapeutics include oral and topical probiotics, prebiotics, postbiotics, fecal microbiota transplantation (FMT), and novel, next-generation drugs, and could be considerable. Anti-obesity therapies targeting the gut microbiome may be used off-label, including FMT, synbiotics, and prebiotics. Potential side effects, such as innate immune complications and pathogen transmission, as well as other risks, could result from gut microbiome-modifying therapeutics. Concerns about failing to reproduce efficacy or safety results noted in preclinical models. Regulation efforts are under study; however, only occasional studies of the safety and efficacy of gut microbiome modifying therapeutics by EU and US regulators have been completed. The rapidly growing interest in regulating gut microbiome therapeutics presented obstacles to developing products concurrently with regulatory efforts. Little empirical research on the safety and efficacy of gut microbiome-modifying products has been conducted, partially due to regulation priorities but also due to a reluctance of regulators to implement legislation in an area of rapid science. Of concern is that the market is developing while there are currently no comprehensive databases listing approved clinical studies, commercial products/therapeutics, or details on the ethical approval status of studies. Commercial interests, compounded by diverse regulatory and ethical environments in different countries, cause potential asymmetries in the availability of products. The public, professionals, and researchers currently lack the necessary information to navigate regulatory environments and product markets. Efforts to develop compatible, evidence-based, and relevant regulations regarding both research and commercialization are presented by ongoing, multi-stakeholder management. Ultimately, regulatory strategies and public policy regarding gut microbiome therapeutics can inform ongoing efforts to engage broad public discussion. Access to detailed data on ongoing and completed clinical studies worldwide is presented by the. Furthermore, efforts to develop comprehensive knowledge databases can facilitate the development of academia-industry collaborations and scientific discussions about research gaps and commercial needs [21, 22].

Ethical Considerations in Microbiome Research

The microbiome, which is the cohabitation of the human genome by the genomes of the bacteria and viruses that occupy our bodies, includes all the microbial communities that aggregate in the human body. This new organism consists of tens of trillions of an estimated 1,000 different species of prokaryotes (bacteria and archaea) and eukaryotes (fungi, protozoa, and viruses). The National Institute of Health has begun the Human Microbiome Project, whose goal is to ascertain the diversity of microbial communities that inhabit the body, to identify the genes they carry, and to explore the relationships between the microbiota and their human hosts. Collectively, these organisms are called the microbiome, with which we coexist symbiotically and mutually benefit from each other's consumer and waste products. The study of the microbiome will have implications for public policy, law, and philosophy, as well as reforms of the legal system. The advent of proposers of such studies is likely to produce new kinds of intellectual property claims based on ownership of fermented food products, probiotics, and prebiotics, as well as the identification of microorganisms involved in industrial manufacturing processes; see, for example, the patent claims on the bacterium used to make the dairy product called yogurt, and attempts to follow suit

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

with other microbial fermentation products. Understanding the microbiome and the biology of its organisms' interactions with their human host will necessitate further changes in the medical view of health and disease. In the past, the human host was viewed as an organism made ill through genetic mutations or anomalies. Germs were also thought of as harmful invaders that caused illness. However, the current view is that organisms such as fungi, archaea, and bacteria cohabitate the body, most of the time harmlessly, with a symbiotic relationship. A healthy human being holds about 10 times more microbial cells than human cells [23, 24].

Future Directions in Microbiome Studies

Our ability to rapidly characterize the microbiome, including metagenomic and metatranscriptomic methods, will create the bioinformatic pipelines and biostatistical methods required for its analysis. These advances will allow clinical microbiome studies to move from bench to bedside, where the development of diagnostics and therapeutics will require novel criteria based on the health of the microbiome and metabolic output instead of microbial membership alone. Critically, it is this field's loudest call to arms to seek to understand underlying mechanisms for correlative studies, to move from association to causation. Why does the development and/or alteration of the microbiome promote the amelioration of a particular disease? Currently, efforts to alter the microbiome for preventive or therapeutic purposes via gnotobiotic models, dietary manipulation, or fecal microbiota transplantation focus solely on the composition and diversity of the resultant microbial community. Any one microbiome can be seen in any number of states, ranging from health to dysbiosis. To improve therapeutic efficacy and prediction of outcomes, it would be prudent to identify mechanisms that result in improved clinical endpoints. The nomination of therapeutic probiotic strains on the basis of their presence in successful clinical trials suggests a new path for successful treatment. Heptaprenyl tetraphosphate was likely the effector metabolite, acting on a GPR109A-dependent axis of immune modulation. Further investigation of microbial factors with newly developed specific experimental tests should yield a wealth of mechanistic information in this regard. Fructo- and galacto-oligosaccharides, inulin, arabinogalactan, polyunsaturated fatty acids, and emulsifiers have recently been shown to modulate the microbial community structure and diversity, alter metabolic output, and induce apical gut physiology. Condition modulation of the gut microbiome via dietary intervention is currently being monitored in numerous clinical studies. Transcriptional profiling of microbial communities indicated that divergence from health had the potential to engender loss of function, which could be investigated using treatments such as microbial restoration and substrate administration to mitigate disease [25-29].

CONCLUSION

The human microbiome stands at the crossroads of multiple physiological systems, acting as a keystone player in immune regulation, metabolism, and even neurobehavioral health. This paper highlights how early microbial exposures, dietary influences, and environmental factors shape microbial communities throughout the human lifespan. Mounting evidence links disruptions in microbiome composition, dysbiosis, to a host of chronic diseases, offering new perspectives on prevention and treatment. While technological advances in sequencing and computational biology have enabled unprecedented insight into microbial ecology, significant gaps remain in translating these discoveries into clinically actionable strategies. Future research must prioritize integrative systems biology approaches, longitudinal cohort studies, and precision interventions to harness the microbiome's therapeutic potential. Understanding and preserving microbiome integrity may hold the key to managing a wide spectrum of health conditions and enhancing well-being across populations.

REFERENCES

1. Suchiita A, Gupta N, Nandi K, Sonkar S, Chandra L. Harmony within: unravelling the microbiome–immune system symbiosis for health. Advanced Gut & Microbiome Research. 2025;2025(1):9927379. wiley.com
2. Lewis Jr CM, Akinyi MY, DeWitte SN, Stone AC. Ancient pathogens provide a window into health and well-being. Proceedings of the National Academy of Sciences. 2023 Jan 24;120(4):e2209476119. pnas.org
3. Bosch TC, Wigley M, Colomina B, Bohannan B, Meggers F, Amato KR, Azad MB, Blaser MJ, Brown K, Dominguez-Bello MG, Ehrlich SD. The potential importance of the built-environment microbiome and its impact on human health. Proceedings of the National Academy of Sciences. 2024 May 14;121(20):e2313971121. pnas.org

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

4. Gilbert JA, Hartmann EM. The indoor microbiome and human health. Nature Reviews Microbiology. 2024 Dec;22(12):742-55.
5. Smail SW, Albarzinji N, Salih RH, Taha KO, Hirmiz SM, Ismael HM, Noori MF, Azeez SS, Janson C. Microbiome dysbiosis in SARS-CoV-2 infection: implication for pathophysiology and management strategies of COVID-19. Frontiers in Cellular and Infection Microbiology. 2025 Apr 22;15:1537456.
6. Segata N, Haake SK, Mannon P, Lemon KP, Waldron L, Gevers D, Huttenhower C, Izard J. Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat, and stool samples. Genome biology. 2012 Jun;13:1-8.
7. Dogra SK, Chung CK, Wang D, Sakwinska O, Colombo Mottaz S, Sprenger N. Nurturing the early life gut microbiome and immune maturation for long term health. Microorganisms. 2021 Oct 7;9(10):2110.
8. Ongesa TN, Ugwu OP, Ugwu CN, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Okon MB, Ejemot-Nwadiaro RI. Optimizing emergency response systems in urban health crises: A project management approach to public health preparedness and response. Medicine. 2025 Jan 17;104(3):e41279.
9. Rackaityte E, Lynch SV. The human microbiome in the 21st century. Nature Communications. 2020 Oct 16;11(1):5256.
10. van den Berg NI, Machado D, Santos S, Rocha I, Chacón J, Harcombe W, Mitri S, Patil KR. Ecological modelling approaches for predicting emergent properties in microbial communities. Nature ecology & evolution. 2022 Jul;6(7):855-65. nih.gov
11. Natalini JG, Singh S, Segal LN. The dynamic lung microbiome in health and disease. Nature Reviews Microbiology. 2023 Apr;21(4):222-35.
12. Brodin P. Immune-microbe interactions early in life: A determinant of health and disease long term. Science. 2022 May 27;376(6596):945-50.
13. Ugwu CN, Ugwu OP, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Ejemot-Nwadiaro RI, Okon MB, Egba SI, Uti DE. Medical preparedness for bioterrorism and chemical warfare: A public health integration review. Medicine. 2025 May 2;104(18):e42289.
14. Chand D, Kumari A, Kaushal L, Arya E, Kumar P. Oral microbiome and longevity. InOral Microbiome 2025 (pp. 302-326). CRC Press.
15. Chen Y, Zhou J, Wang L. Role and mechanism of gut microbiota in human disease. Frontiers in cellular and infection microbiology. 2021 Mar 17;11:625913. frontiersin.org
16. Kunst C, Schmid S, Michalski M, Tümen D, Buttenschön J, Müller M, Gülow K. The influence of gut microbiota on oxidative stress and the immune system. Biomedicines. 2023 May 8;11(5):1388. mdpi.com
17. Hrncir T. Gut microbiota dysbiosis: triggers, consequences, diagnostic and therapeutic options. Microorganisms. 2022 Mar 7;10(3):578.
18. Perrotta G. The intestinal microbiota: Towards a multifactorial integrative model. Eubiosis and dysbiosis in morbid physical and psychological conditions. Archives of Clinical Gastroenterology. 2021 May 19;7(2):024-35.
19. Ugwu OP, Alum EU, Ugwu JN, Eze VH, Ugwu CN, Ogenyi FC, Okon MB. Harnessing technology for infectious disease response in conflict zones: Challenges, innovations, and policy implications. Medicine. 2024 Jul 12;103(28):e38834.
20. Manos J. The human microbiome in disease and pathology. Apmis. 2022 Dec;130(12):690-705.
21. Ronan V, Yeasin R, Claud EC. Childhood development and the microbiome—the intestinal microbiota in maintenance of health and development of disease during childhood development. Gastroenterology. 2021 Jan 1;160(2):495-506.
22. Flandroy L, Poutahidis T, Berg G, Clarke G, Dao MC, Decaestecker E, Furman E, Haahtela T, Massart S, Plovier H, Sanz Y. The impact of human activities and lifestyles on the interlinked microbiota and health of humans and ecosystems. Science of the total environment. 2018 Jun 15;627:1018-38.
23. Abdul-Aziz MA, Cooper A, Weyrich LS. Exploring relationships between host genome and microbiome: New insights from genome-wide association studies. Frontiers in Microbiology. 2016 Oct 12;7:1611.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

24. Pribyl AL, Hugenholtz P, Cooper MA. A decade of advances in human gut microbiome-derived biotherapeutics. Nature Microbiology. 2025 Jan 8:1-2.
25. Gulliver EL, Young RB, Chonwerawong M, D'Adamo GL, Thomason T, Widdop JT, Rutten EL, Rossetto Marcelino V, Bryant RV, Costello SP, O'Brien CL. The future of microbiome-based therapeutics. Alimentary Pharmacology & Therapeutics. 2022 Jul;56(2):192-208. wiley.com
26. Liang G, Bushman FD. The human virome: assembly, composition, and host interactions. Nature Reviews Microbiology. 2021 Aug;19(8):514-27.
27. Joos R, Boucher K, Lavelle A, Arumugam M, Blaser MJ, Claesson MJ, Clarke G, Cotter PD, De Sordi L, Dominguez-Bello MG, Dutilh BE. Examining the healthy human microbiome concept. Nature Reviews Microbiology. 2025 Mar;23(3):192-205. google.com
28. Olendzki B, Bucci V, Cawley C, Maserati R, McManus M, Olednzki E, Madziar C, Chiang D, Ward DV, Pellish R, Foley C. Dietary manipulation of the gut microbiome in inflammatory bowel disease patients: Pilot study. Gut Microbes. 2022 Dec 31;14(1):2046244. tandfonline.com
29. Attaye I, Warmbrunn MV, Boot AN, van der Wolk SC, Hutten BA, Daams JG, Herrema H, Nieuwdorp M. A systematic review and meta-analysis of dietary interventions modulating gut microbiota and cardiometabolic diseases Striving for new standards in microbiome studies. Gastroenterology. 2022 Jun 1;162(7):1911-32. sciencedirect.com

CITE AS: Nassimbwa Kabanda D. (2025). Understanding the Human Microbiome: Implications for Health. Research Output Journal of Biological and Applied Science 5(3):140-147. https://doi.org/10.59298/ROJBAS/2025/53140147

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited